NCT06482554View on ClinicalTrials.gov

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
ApathySchizophreniaSchizophrenia; Psychosis
Interventions
DRUG

Lumateperone 42 mg

Standard treatment with lumateperone

DRUG

Risperidone 2 mg

Standard treatment with other antipsychotic drugs

Trial Locations (1)

71101

RECRUITING

LSU Health Shreveport, Shreveport

All Listed Sponsors
lead

Louisiana State University Health Sciences Center Shreveport

OTHER